Idalopirdine

Idalopirdine

Clinical data
ATC code	None
Identifiers
IUPAC name 2-(6-Fluoro-1H-indol-3-yl)-N-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)ethanamine
Synonyms	Lu-AE-58054
CAS Number	467459-31-0 N
ChemSpider	19878969 N
ChEMBL	CHEMBL3286580
Chemical and physical data
Formula	C20H19F5N2O
Molar mass	398.37 g/mol
3D model (Jmol)	Interactive image
SMILES FC(F)C(F)(F)COc1cccc(c1)CNCCc3cnc2cc(F)ccc23
InChI InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2 N Key:YBAWYTYNMZWMMJ-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Idalopirdine (INN) (code names Lu AE58054, SGS-518) is a potent and selective 5-HT₆ receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia. As of October 2013 it is in phase III clinical trials.

A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose. Two further phase III trials are due to report in early 2017.

See also

• Cerlapirdine
• Latrepirdine

External links

• Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia
• Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease